Watanabe H, Ohe H, Ando K, Sawamura Y, Niijima T, Nakamura S, Orikasa S, Tanahashi Y, Imamura K, Yoshida H
Prostate. 1981;2(2):155-61. doi: 10.1002/pros.2990020205.
Transrectal ultrasonotomography was performed in 44 patients with prostatic cancer before, during, and after estramustine phosphate (Estracyt) administration. In 75.7% of 37 previously untreated patients, the deformity of the horizontal section of the prostate with prostatic cancer was corrected considerably, while in 89.2%, prostatic weight was remarkably reduced. In 57.1% of seven previously treated patients, appreciable changes were also observed in the shape and weight of the prostate. We concluded that estramustine phosphate was effective not only for untreated prostatic cancer, but also, at least in some degree, for relapsed cases.
对44例前列腺癌患者在给予磷酸雌莫司汀（癌腺治）之前、期间及之后进行了经直肠超声断层扫描。在37例先前未接受治疗的患者中，75.7%的前列腺癌患者前列腺水平断面的畸形得到了明显矫正，而89.2%的患者前列腺重量显著减轻。在7例先前接受过治疗的患者中，57.1%的患者前列腺的形状和重量也出现了明显变化。我们得出结论，磷酸雌莫司汀不仅对未治疗的前列腺癌有效，而且至少在一定程度上对复发病例也有效。
